



## ASX ANNOUNCEMENT

### Investor Webinar Invitation – Reducing Diagnostic Uncertainty

**MELBOURNE, Australia (07 January 2026)** – Lumos Diagnostics Holdings Ltd (ASX:LDX, “Lumos” or the “Company”) a leader in rapid, point-of-care diagnostic technologies, is pleased to invite shareholders and investors to an upcoming webinar titled, “Reducing Diagnostic Uncertainty.”

The webinar will explore how outpatient and urgent care providers are using evidence-based antibiotic stewardship strategies supported by the FebriDx® rapid diagnostic test. The session will take place on Friday, 9 January 2026 at 4:00 AM AEDT via Zoom.

During the webinar, participants will learn how FebriDx® supports more confident decision-making during the busy cold and flu season. The discussion will include real-world insights from WellStreet Urgent Care, where FebriDx® has been integrated into high-volume workflows to improve diagnostic clarity, strengthen stewardship practices, and enhance clinical efficiency.

Speakers include Annie Bell, Vice President of Medical Affairs at Lumos Diagnostics, and Dr Brian Bobb, Senior Medical Officer at WellStreet Urgent Care.

Additional information and investor registration can be accessed via the event link below.

[Event Information and Registration for the Webinar](#)

A recording of the session will be made available to all registered participants after the event.

**-Ends-**

***This announcement has been approved by the Lumos Disclosure Committee.***

#### **About Lumos Diagnostics**

*Lumos Diagnostics specializes in rapid and complete point-of-care diagnostic test technology to help healthcare professionals more accurately diagnose and manage medical conditions. Lumos offers customized assay development and manufacturing services for point-of-care tests and proprietary digital reader platforms. Lumos also directly develops, manufactures, and commercializes novel Lumos-branded point-of-care tests that target infectious and inflammatory diseases.*

*For more information visit [lumosdiagnostics.com](http://lumosdiagnostics.com).*

## About WellStreet Urgent Care

*WellStreet's mission is to ensure both patients and partners feel valued and well cared for. WellStreet are experts in developing and operating retail Urgent Care networks, leading with the Health System brand to promote community awareness and minimal patient confusion. We combine a proprietary, industry-leading digital patient experience platform with fully integrated Electronic Medical Records systems to provide a best-in-class patient experience where all downstream care coordination friction points are removed.*

*For more information visit [wellstreet.com](http://wellstreet.com).*

### **Bios of Speakers**

[Annie Bell | LinkedIn](#)

[Brian Bobb | LinkedIn](#)

### **Forward-Looking Statements**

*This announcement contains forward-looking statements, including references to forecasts. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions, and other important factors, many of which are beyond Lumos' control and speak only as of the date of this announcement. Readers are cautioned not to place undue reliance on forward-looking statements.*

#### **Media Contacts:**

Haley Chartres – Australia

H^CK Director

[haley@hck.digital](mailto:haley@hck.digital)

+61 423 139 163

#### **Investor Contact:**

George Kopsiaftis

IR Specialist, IR Department

[ir@lumosdiagnostics.com](mailto:ir@lumosdiagnostics.com)

+61 409 392 687

#### **Company Registered Office:**

Lumos Diagnostics Holdings Ltd

Suite 2, Level 11

385 Bourke Street

Melbourne VIC 3000

[info@lumosdiagnostics.com](mailto:info@lumosdiagnostics.com)

+61 3 9087 1598